Fig. 1.1 Estimated age-standardized incidence of overall cancers per 100,000 in different countries (Extracted from) More than the environment, host-related characteristics are also major determinants of cancer incidence. Since cancer…
Fig. 18.1 Polarization of tumor-associated macrophages in glioma. Notice the distinct M1 and M2 phenotypes (Reprinted from Li and Graeber [18], with permission) Alternatively activated M2-type TAMs are the predominant…
Fig. 13.1 A stepwise development of CRC includes ACF, adenoma, and adenocarcinoma formation which eventually metastasize. ACFs preneoplastic lesions are develop when an insult occurs in the colonic mucosa upon…
Fig. 10.1 Schematic presentation of immune cells in the cancer microenvironment In the setting of hepatocarcinogenesis, the most important predisposing factor is chronic HBV infection. The genome of HBV alters…
Fig. 16.1 MRI scan, horizontal layer at the level of the basis of the tongue, presenting the tumor area at the right site and a group of lymph nodes at…
Fig. 24.1 Pathogenesis of graft-versus-host disease (GVHD) can be divided into three phases. In the first phase, the host is conditioned by myeloablative treatment. This leads to tissue damage with…
© Springer-Verlag Berlin Heidelberg 2015Nima Rezaei (ed.)Cancer Immunology10.1007/978-3-662-46410-6_23 23. Immunology and Immunotherapy of Breast Cancer John Stagg1 and Sherene Loi2 (1) Centre de Recherche du Centre Hospitalier de l’Université de Montréal, 900 St-Denis Street Montreal, Montreal,…
29. Bennaceur K, Chapman JA, Touraine J-l, Portoukalian J. RETRACTED: immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochi Biophys Acta (BBA)-Rev Cancer. 2009;1795(1):16–24. 30. Kalluri…
4. Chakrabarti A, Verbridge S, Stroock AD, Fischbach C, Varner JD. Multiscale models of breast cancer progression. Ann Biomed Eng. 2012;40:2488–500.PubMed 5. Taddei ML, Giannoni E, Comito G, Chiarugi P….
15. Lamm DL, Bluemenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma…
